Abstract
OPINION article Front. Microbiol., 20 August 2013Sec. Antimicrobials, Resistance and Chemotherapy Volume 4 - 2013 | https://doi.org/10.3389/fmicb.2013.00240
Highlights
Since the report of streptomycin from the strains of Streptomyces griseus there has been a rapid escalation in antibiotic discovery from the genus Streptomyces
It has been evidenced by continuing production of string of commercially important antibiotics like daptomycin, erythromycin, fosfomycin, lincomycin, neomycin, streptomycin, and tetracycline from industrially-important members of the genus Streptomyces (Mahajan and Balachandran, 2012)
The likelihood of finding novel antimicrobial leads from these distinctive actinomycetes has recently dwindled upon the rediscovery of known compounds (Koehn and Carter, 2005) and the focus of current microbial drug discovery programs being reoriented toward other promising microbial resources
Summary
Since the report of streptomycin from the strains of Streptomyces griseus there has been a rapid escalation in antibiotic discovery from the genus Streptomyces (largest genus of Actinobacteria). The likelihood of finding novel antimicrobial leads from these distinctive actinomycetes has recently dwindled upon the rediscovery of known compounds (Koehn and Carter, 2005) and the focus of current microbial drug discovery programs being reoriented toward other promising microbial resources. Rare actinomycetes (non-streptomycetes) are currently isolated from diverse environments and intensively studied for potential leads for antibiotic discovery programs.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
